Philip Sinclair
About Philip Sinclair
Philip Sinclair is the Vice President of Medical Affairs, Interventional Oncology at Boston Scientific, with extensive experience in medical strategy and operations across various companies.
Company
Philip Sinclair currently serves as Vice President, Medical Affairs in the Interventional Oncology division at Boston Scientific. He started at Boston Scientific in 2019 and is responsible for steering medical strategy and operations within the interventional oncology sector.
Title
Philip Sinclair holds the title of Vice President, Medical Affairs, Interventional Oncology, at Boston Scientific. His role involves overseeing the development and implementation of medical strategies and ensuring alignment with overall company objectives in the field of interventional oncology.
Professional Background
Philip Sinclair has an extensive background in medical affairs and research. Before joining Boston Scientific, he worked as Vice President, Medical Affairs at BTG plc from 2015 to 2019. Prior to that, he served as Senior Director, Medical Strategy and Operations at BTG plc from 2013 to 2015. He also held the role of Director, Medical Affairs at Nordion in 2013. Sinclair has broad experience, having worked as an advisor at Atherochem and BioQuest Therapeutics, as Chief Scientific Officer at Allphase Clinical Research, and in various roles at other organizations.
Education and Expertise
Philip Sinclair earned a PhD in Toxicology from the University of Guelph, where he studied from 2000 to 2004. Prior to this, he completed an MSc in Endocrinology from the same university, studying from 1997 to 2000. His academic foundation in animal biology, culminating in a BSc from the University of Guelph from 1992 to 1996, equipped him with multifaceted expertise applicable to his professional roles in medical and scientific affairs.